AAPA

The American Academy of Physician Assistants is pleased to announce the current Chapter Lecture Series program. This program provides the opportunity for your chapter to have one speaker from the current topics available listed below. Each lecture provided will be fully funded by AAPA; all of the speaker's expenses including speaker travel, honoraria, hotel, and meals will be covered by AAPA. In addition to paying speaker expenses, AAPA will provide your organization a stipend of $1,000-$3,000 upon receipt of the completed Chapter Lecture Series evaluation form.

Here are the scheduling criteria for AAPA's Chapter Lecture Series:

• CLS sessions should not be scheduled on the first or last day of a conference
• CLS sessions should not be scheduled during the first or last time slots of the day
• CLS sessions should not run concurrently with other sessions
• CLS sessions must be held in the same facility as the majority of the conference

If you are interested in participating, please fill out the information form provided below with the date and time you would prefer the lecture be scheduled. The lecture will be presented in 60 minutes. Once a speaker is assigned to your meeting, you will be provided with that speaker's contact information to finalize the presentation date and time. All speaker costs will be paid directly by the AAPA and you will receive the stipend described above from AAPA once we are in receipt of your completed evaluation form. Your organization must acknowledge the support of these sessions by AAPA and the supporting company in your promotional materials and on-site materials and introductions.

Click here for request form

Click here for evaluation form

Topics Available

Atrial Fibrillation

Available for meetings completed by June 30, 2011
Treatment for Atrial fibrillation: Current options and a look to the future supported by Boehringer-Ingelheim Pharmaceuticals Ltd.
At the conclusion of the program, participants will be able to:

1. Describe the current epidemiology and prognosis seen in atrial fibrillation
2. Review the pathophysiological mechanisms of atrial fibrillation
3. Identify strategies to risk stratify patients with atrial fibrillation
4. Compare strategies for managing rate vs. rhythm control in atrial fibrillation
5. Evaluate the benefit and limitations of antiarrhythmic and anticoagulation therapies
6. Discuss the important aspects of patient education in atrial fibrillation

This Chapter Lecture Series program is supported by Boehringer-Ingelheim Pharmaceuticals Ltd. This session should be listed in your program promotional materials, as well as in your Final Program as "This session is presented through the AAPA Chapter Lecture Series, which is supported by an unrestricted educational grant from Boehringer-Ingelheim Pharmaceuticals Ltd."

Attention Deficit Hyperactivity Disorder

Available for programs occurring between March 1, 2010 and June 30, 2011
Attention Deficit Hyperactivity Disorder - ADHD supported by an educational grant from McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC
At the conclusion of the program, participants will be able to:

1. List the criteria for diagnosis of ADHD
2. Discuss the prevalence of ADHDA and its impact on society
3. Discuss one screening tool for ADHD
4. Describe the risks and benefits of using stimulant medications to treat ADHD.
5. Review all FDA approved medications for ADHD

This Chapter Lecture Series program is supported by McNeil Pediatrics, Division of Ortho-McNeil Janssen Scientific Affairs, LLC. This session should be listed in your program promotional materials, as well as in your Final Program as "This session is presented through the AAPA Chapter Lecture Series, which is supported by an unrestricted educational grant from McNeil Pediatrics, Division of Ortho-McNeil Janssen Scientific Affairs, LLC".

 

COPD-Asthma

Available for meetings completed by December 31, 2010
COPD-Asthma supported by Boehringer-Ingelheim Pharmaceuticals Ltd.
At the conclusion of this presentation, participants will be able to:

1. Define COPD and asthma and describe the pathophysiologic processes that lead to small airway obstruction and reversible airway obstruction
2. Recognize and differentiate the clinical presentation of COPD exacerbation from asthma exacerbation
3. Distinguish the medical management of patients with COPD exacerbation from those with stable COPD
4. Explain how spirometry can be useful in the diagnosis of COPD and asthma
5. List risk factors for severity of disease in asthma and risk indications for COPD

This Chapter Lecture Series program is supported by Boehringer-Ingelheim Pharmaceuticals Ltd. This session should be listed in your program promotional materials, as well as in your Final Program as "This session is presented through the AAPA Chapter Lecture Series, which is supported by an unrestricted educational grant from Boehringer-Ingelheim Pharmaceuticals Ltd. "

 

Diabetes

Available for meetings completed by December 31, 2010
Type 2 Diabetes Management: What's New on the Horizon supported by Merck & Co. Inc.
At the conclusion of this presentation, participants will be able to

1. Define Type 2 Diabetes Mellitus (T2DM) and explain the pathophysiologic processes that can lead to hyperglycemia.
2. Review recent clinical data on T2DM
3. Review the impact on T2DM on special populations, including the elderly and various ethnic groups
4. Review advances in therapeutic options

This Chapter Lecture Series program is supported by Merck. This session should be listed in your program promotional materials, as well as in your Final Program as "This session is presented through the AAPA Chapter Lecture Series, which is supported by an unrestricted educational grant from Merck".

Available for meetings between April 1, 2010 and July 31, 2011
Type 2 Diabetes: Treatment Strategies for 2010 with a Focus on Incretin-Based Therapies supported by educational grants from Novo Nordisk and Bristol-Myers Squibb, with partial support from Lilly
At the conclusion of the program, participants will be able to:

1. Discuss the underlying pathophysiology of Type 2 diabetes and how this impacts treatment decisions.
2. Describe the role of incretins in the first-phase insulin response in patients with Type 2 diabetes.
3. Discuss how incretin based therapies improve cardiovascular markers.
4. Review pharmacologic therapies available for treating Type 2 diabetes and discuss the ADA/EASD and AACE guidelines for therapy.
5. Using a case study format, develop a plan to incorporate incretin based therapies to obtain optimal diabetes management.

This Chapter Lecture Series program is supported by educational grants from Novo Nordisk and Bristol-Myers Squibb, with partial support from Lilly. This session should be listed in your program promotional materials, as well as in your Final Program as "This session is presented through the AAPA Chapter Lecture Series, which is supported by educational grants from Novo Nordisk and Bristol-Myers Squibb, with partial support from Lilly ".

 

Female Sexual Disorders

Available for meetings completed by October 31, 2010
Female Sexual Disorders: Enhancing communication supported by Boehringer-Ingelheim Pharmaceuticals Ltd.
At the conclusion of this presentation, participants should be able to:

1. Describe prevalence and importance of female sexual disorders (FSD)
2. Define FSD and explain their physiological and psychological components
3. Outline communication techniques that identify sexual concerns, overcome barriers, and increase comfort level in discussing sexual health

This Chapter Lecture Series program is supported by Boehringer-Ingelheim Pharmaceuticals Ltd. This session should be listed in your program promotional materials, as well as in your Final Program as "This session is presented through the AAPA Chapter Lecture Series, which is supported by an unrestricted educational grant from Boehringer-Ingelheim Pharmaceuticals Ltd."

 

HIV

Available for meetings completed by December 31, 2010
Identifying and Making First Decisions for the Primary Care Patient with HIV: A Step-by-Step Guide through the Initial Clinical Encounter supported by Bristol-Myers Squibb, Gilead Sciences, Inc., and Tibotec Therapeutics
At the conclusion of this session, participants should be able to:

1. List two benefits of routine screening for HIV infection
2. Perform the appropriate examinations and laboratory tests at the first clinical encounter with a newly diagnosed patient with HIV
3. Utilize current recommendations in the consideration of an antiretroviral treatment regimen
4. Discuss other pertinent issues for the first encounter with an HIV-positive patient, including education, counseling, and mental health issues

This Chapter Lecture Series program is supported by Bristol-Myers Squibb, Gilead Sciences, Inc., and Tibotec Therapeutics. This session should be listed in your program promotional materials, as well as in your Final Program as "This session is presented through the AAPA Chapter Lecture Series, which is supported by an unrestricted educational grant from Bristol-Myers Squibb, Gilead Sciences, Inc., and Tibotec Therapeutics".

Overactive Bladder

Available for meetings completed by December 31, 2010
Overactive Bladder - Diagnosis and Treatment in Primary Care supported by Pfizer
At the conclusion of the program, participants will be able to:

1. Define overactive bladder and identify risk factors for this condition
2. Discuss and incorporate screening tools in their practice to identify patients with overactive bladder
3. Describe the proper evaluation of patients suspected of having overactive bladder
4. List the nonpharmacologic treatment interventions for overactive bladder
5. List the pharmacologic interventions available for overactive bladder

This Chapter Lecture Series program is supported by Boehringer-Ingelheim Pharmaceuticals Ltd. This session should be listed in your program promotional materials, as well as in your Final Program as "This session is presented through the AAPA Chapter Lecture Series, which is supported by an unrestricted educational grant from Boehringer-Ingelheim Pharmaceuticals Ltd."

 

Click here for request form

Click here for evaluation form

If you and would like to participate, or if you have additional questions that are not covered here, please contact Shelley L. Hicks at 703/836-2272, ext. 3402 or by e-mail at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .